

Contribution of IgG avidity and PCR for the early diagnosis of toxoplasmosis in pregnant women from the North-Eastern region of Algeria.

Hajira Berredjem^{1,2}, Hayette Aouras³, Meriem Benlaifa², Imène Bechecker¹, Mohamed Reda Djebar²

1. Department of Biochemistry, Faculty of Sciences, University of Badji Mokhtar, Annaba, Algeria
2. Laboratory of Cellular Toxicology, Faculty of Sciences, University of Badji Mokhtar, Annaba, Algeria
3. Service of Gynecology, EHS Abdallah Nouaouria Hospital, El Bouni-Annaba, Algeria

Abstract:

Background: Acute toxoplasmosis in pregnant women presents a high risk of *Toxoplasma* transmission to the fetus. Early diagnosis is difficult, especially when serological testing for IgG/IgM antibodies fail to differentiate between a recent and a past infection. In this case, we rely on IgG avidity or PCR assays.

Objectives: The aim of this study was to compare conventional ELISA and IgG avidity, with PCR using B1 and P30 primers for the early diagnosis of toxoplasmosis in pregnant women.

Methods: Sera were collected from 143 pregnant women and measured by ELISA for anti-*Toxoplasma* IgG, IgM, IgA and IgG avidity. DNA was extracted from 57 peripheral blood and 14 amniotic fluid samples for PCR amplification.

Results: A total of 57 out 143 women were seropositive: 30 (52.6%) were IgG+/IgM- and 27 (43.8%) were IgG+/IgM+; IgA antibodies were positive in 7 (12.2%) cases. IgG avidity was low in 9 women suggesting an acute infection; 3 women presented an intermediate avidity. PCR detected *Toxoplasma* DNA in 9 women presenting low avidity and was negative for the intermediate avidity cases.

Conclusion: PCR combined to avidity IgG performed better than ELISA IgG, IgM and/or IgA assays alone. PCR was useful in the case of intermediate avidity.

Keywords: Toxoplasmosis, pregnant women, serology, IgG avidity, PCR.

DOI: <https://dx.doi.org/10.4314/ahs.v17i3.7>

Cite as: Berredjem H, Aouras H, Benlaifa M, Bechecker I, Djebar MR. Contribution of IgG avidity and PCR for the early diagnosis of toxoplasmosis in pregnant women from the North-Eastern region of Algeria. *Afri Health Sci.* 2017;17(3): 647-656. <https://dx.doi.org/10.4314/ahs.v17i3.7>

Introduction:

Toxoplasmosis, caused by the intracellular parasite *Toxoplasma gondii* (*T gondii*), is one of the most prevalent diseases in humans¹. This disease is generally asymptomatic in immunocompetent human host². However, *T gondii* causes substantial morbidity and mortality in immunocompromised patients^{3,4} and in congenitally infected infants⁵. Infection acquired by pregnant women immediate-

ly before or during gestation and its transmission to the fetus continues to be the cause of tragic yet preventable diseases, which may be more or less severe depending on the date of transmission⁶. Congenital infection acquired during the early stages of pregnancy often results in severe fetal signs such as severe neurological damages, or fetal death. Infection acquired later, within the second or third trimester, is more likely to be asymptomatic at birth leading usually to much less severe injury of the newborn and later of the child⁷. A rapid and accurate diagnosis is required in order to start the relatively efficient anti-parasitic treatment⁸.

Current diagnosis of toxoplasmosis relies mainly on serological detection of specific IgG and IgM, on fibroblast cell culture or mice inoculation of amniotic fluid or fetal blood^{3,9}. The presence of IgM is, in general, an indication that the host has recently been infected. However, these antibodies can persist for months or even years after acute infection. Consequently, the concomitant presence

Corresponding author:

Hajira Berredjem,
Department of Biochemistry,
Faculty of Sciences,
University of Badji Mokhtar
PO Box 12 Sidi Amar 23000, Annaba (Algeria)
Tel: (00213) 38-87-10-61
hajira.berredjem@univ-annaba.dz
and h_berjem@yahoo.fr

of IgM and IgG does not always indicate an acute infection, so it is necessary to study antibody kinetics based on a serological control 2-3 weeks later¹⁰. Moreover, serological testing may fail during the active phase of *T. gondii* infection because the antibodies titres are low; therefore, the high risk of congenital toxoplasmosis of a fetus may be undetected because the pregnant mother might test negative during the active phase of *T. gondii* infection. When high levels of IgG antibodies are present in sera, serological testing does not distinguish a recent infection from one acquired a longtime before and detection of specific IgM response cannot help determine if infection was recent¹¹. This inconvenience has limited the use of the serological tests. More studies have shown that IgG avidity assay^{10,14,15} or polymerase chain reaction (PCR)^{12,13} are useful for identification or exclusion of *T. gondii* acute infection, or for estimation at the time of seroconversion.

In this study, IgG avidity and PCR have been evaluated, on the basis of the results obtained with conventional serological tests, as a diagnostic tool for the diagnosis of toxoplasmosis in Algerian pregnant women, and for the discrimination between acute and chronic infection.

Patients and methods:

This prospective study was carried out at Abdallah Nouaouria Hospital, El Bouni-Annaba. Peripheral blood (PBL) and amniotic fluid (AF) samples were collected during diagnosis for toxoplasmosis in 143 pregnant women, between 22 and 43 years old. None of the mothers had apparent symptoms of toxoplasmosis during their pregnancy and no antibiotic drugs were previously prescribed to the patients. Two blood samples, with respectively an interval of 21 days, were taken from each patient. Therefore, a total of 286 sera samples were checked for anti-*Toxoplasma* antibodies by serological tests : IgG, IgM and IgA ELISA assay. A total of 57 samples (one sample from each patient) with a positive anti-*Toxoplasma* IgG were further analysed using the IgG avidity. Blood and AF samples were taken for DNA extraction. Gene amplification was processed on 57 PBL samples; PCR on AF was done to 14 women suspected to have acute infection which can lead to a congenital toxoplasmosis. This study was approved by the Hospital Ethical Committee, and informed consent was obtained from all the patients.

IgG, IgM and IgA ELISA

All patients' sera were tested for the presence of specific IgG, IgM and IgA antibodies to *Toxoplasma* using an ELISA kits (Platéla Toxo, Diagnostic Pasteur, France) according to the manufacturer's instructions. The anti-*Toxoplasma* IgG, expressed in IU, were calculated from a standard curve. « Double sandwich » ELISA was used for the detection of IgM and IgA antibodies. Sera samples were processed in duplicate.

IgG avidity

The *Toxoplasma*-specific IgG avidity assay was performed by ELISA (SFRI® laboratoire, France) to discriminate between acute and chronic infection. A total of 57 sera samples were diluted 1/200 and added (100 µl/well) on 2 rows of a plate (row A and row B). After 45 min of incubation at 37°C, the row B was washed 3 times with the modified PBST buffer containing 6 M urea and 4 times with PBST containing 0.05% Tween 20 in order to remove low-avidity antibodies from their binding sites. The control row A was washed 3 times with buffer without urea. The anti-human IgG conjugated with horseradish peroxidase (Dako Glostrup, Denmark) was added with the dilution of 1/1000 in PBST. After incubation and washing, the chromogenic substrate, O-phenylenediamine (Merk, Darmstadt, Germany), was added. The reaction was stopped by addition of sulfuric acid 20%. The absorbance was read at 492 nm. The IgG avidity index (AI: %) was calculated on the basis of the formula : $AI = \text{Abs (PBS-urea)} / \text{Abs(PBST)} \times 100$.

Three different avidity classes were determined: AIs lower than 25%, between 25% and 35%, and above 35% were classified as low, intermediate, and high avidity, respectively.

DNA parasite preparation

DNA extracted from the tachyzoites of *T. gondii*-RH strain (Institut Pasteur, Tunis) was used as positive control for PCR. The parasites were harvested from the peritoneal exudate of Swiss-Webster female mouse intraperitoneally infected 3 days earlier. The DNA parasite was extracted using the salting out method. The concentration of purified DNA was measured by UV spectrophotometry (GENEQUANT, pharmacía Biotech). The DNA samples were stored at -20°C.

Polymerase chain reaction of *T. gondii* B1 and P30 genes

PBL and AF DNA were extracted by the salting out method using the Sodium Chlorure 6 M and precipitated with ethanol¹⁶. The DNA pellet was dissolved in TE buffer and concentrations were then determined.

PCR amplification was carried out in two separate assays : nested PCR, using the 35-fold repetitive DNA region B1 of *T. gondii* primers sets and conventional PCR-ELISA using the major surface antigen P30 gene primers sets. The primer sequences and the expected size of B1 and P30 genes PCR products are shown in Table 1.

Table 1: B1 and P30 Genes primer sequences for the amplification of *T.gondii* DNA.

| Target Gene | Primers | Sequence (5' → 3') | Positions | Size (bp) |
|------------------------|-----------------------|--|-----------|-----------|
| B1 (Nested PCR) | Outer sense strand | Tx2 : TCT TTA AAG CGT TCG TGG TC | 887 - 868 | 193 |
| | Outer nonsense strand | Tx4 : GGA ACT GCA TCC GTT CAT GAG | 694 - 714 | |
| | Inner sense strand | Tx1 : GGC GAC CAA TCT GCG AAT ACA ACC | 853 - 831 | 96 |
| | Inner nonsense strand | Tx3 : TGC ATA GGT TGC AGT CAC TG | 757 - 776 | |
| P30 (PCR-ELISA) | Sense strand | GBI5 : AGC TGG TGG ACG GGG GAT TC | 689 - 709 | 126 |
| | Nonsense strand | GBI6 : GTC TGC ACC GTA GGA GCA CC) | 875 - 895 | |

For nested PCR using the B1 gene, previously described by Burg¹⁷, amplification was carried out in a 50 µl reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl₂ (Promega, France), 0.2 mM of each dNTP (Bohringer Mennheim, Germany), 50 pmol of each primer (Diasorin, Biomedica, Italy), 2.5 U of Taq DNA polymerase (Promega, France) and DNA extracted from each sample. Reactions were run in a Perkin-Elmer thermocycler by using a step cycle program. After initial denaturation of the DNA at 94°C for 5 min, 40 cycles were run : 60 s with a denaturing temperature of 94°C, 60 s with an annealing temperature of 55°C, and 90 s with an extension temperature of 72°C, with a 5 min 72°C extension after the 40 cycles. After the first 40 cycles, 10 µl of each sample was transferred to a second PCR reaction into 40 µl of fresh mixture containing the inner primers pair and the procedure was repeated for 35 cycles.

The conventional PCR-ELISA was assessed for the amplification of the P30 gene¹⁸ using specific primers and under the same conditions as B1 gene for 40 cycles.

Each amplification run included negative and positive

controls. All samples were tested in duplicate. Amplicons were revealed by ethidium bromide on 2% agarose gel electrophoresis, and then visualized under UV illumination.

For P30 gene, detection of hybrids was performed by an ELISA-PCR kit (GEN-ETI-K, DEIA, Diasorin, Italy) as described by the manufacturer. The solid phase was prepared in advance : the wells of a microplate were coated with biotinylated DNA probe (5' TCCCTT GAT-GCAACCGACCACAAA). A result was considered positive when one reaction yielded an amplification product hybridizing to the specific DNA probe.

Results:

Antibody detection

According to respective levels of anti-*Toxoplasma* IgG and IgM in the first positive sample and in the second one, a *Toxoplasma* seropositive status during pregnancy was defined in 57 (39.8%) women. Table 2 shows the huge diversity of the techniques used and presents data on the levels of antibody detection.

Table 2: Serological (ELISA) and molecular (PCR) results from 57 *Toxoplasma* seropositifs pregnant women

| Patient N° | Gestational Age (weeks) | Anti- <i>Toxoplasma</i> antibodies | | | | | DNA amplification (duplicate assays results) | | | |
|------------|-------------------------|------------------------------------|-----|----------|-----------------|-----------|--|-----|----------------------|-----|
| | | IgA | IgM | IgG (IU) | IgG Avidity (%) | Diagnosis | PCR-ELISA (P30 gene) | | Nested PCR (B1 gene) | |
| | | | | | | | Blood | AF | Blood | AF |
| 1 | 16 | + | + | 220 | 18 | AI | +/- | -/- | +/+ | -/- |
| 2 | 16 | - | + | >240 | 63 | CI | -/- | | -/- | |
| 3 | 20 | - | - | >240 | 67 | CI | -/- | | -/- | |
| 4 | 16 | + | + | >240 | 15 | AI | +/+ | -/- | +/+ | -/- |
| 5 | 15 | - | + | >240 | 71 | CI | -/- | -/- | -/- | -/- |
| 6 | 16 | - | + | >240 | 65 | CI | -/- | | -/- | |
| 7 | 8 | - | + | >240 | 20 | AI | +/+ | | +/+ | |
| 8 | 19 | - | + | >240 | 58 | CI | -/- | | -/- | |
| 9 | 12 | - | - | >240 | 47 | CI | -/- | | -/- | |
| 10 | 12 | - | - | >240 | 62 | CI | -/- | | -/- | |
| 11 | 16 | - | + | >240 | 55 | CI | -/- | | -/- | |
| 12 | 13 | - | - | >240 | 49 | CI | -/- | | -/- | |
| 13 | 16 | - | + | 114 | 44 | CI | -/- | -/- | -/- | -/- |
| 14 | 14 | - | + | >240 | 28 | IA | -/- | -/- | -/- | -/- |
| 15 | 15 | + | + | >240 | 21 | AI | +/+ | +/+ | +/+ | +/+ |
| 16 | 8 | - | + | 129 | 70 | CI | -/- | | -/- | |
| 17 | 16 | - | - | 80 | 59 | CI | -/- | | -/- | |
| 18 | 6 | - | - | >240 | 65 | CI | -/- | | -/- | |
| 19 | 16 | - | - | 110 | 51 | CI | -/- | | -/- | |
| 20 | 16 | - | - | >240 | 53 | CI | -/- | | -/- | |
| 21 | 12 | - | + | >240 | 48 | CI | -/- | | -/- | |
| 22 | 8 | - | + | 125 | 47 | CI | -/- | | -/- | |
| 23 | 13 | - | - | 110 | 52 | CI | -/- | | -/- | |
| 24 | 15 | - | + | 180 | 31 | IA | -/- | -/- | -/- | -/- |
| 25 | 16 | - | + | 240 | 68 | CI | -/- | -/- | -/- | -/- |
| 26 | 14 | - | - | 80 | 60 | CI | -/- | | -/- | |
| 27 | 10 | + | + | 240 | 14 | AI | +/+ | | +/+ | |
| 28 | 8 | - | - | 112 | 52 | CI | -/- | | -/- | |
| 29 | 15 | + | + | >240 | 16 | AI | +/+ | +/+ | +/+ | +/+ |
| 30 | 16 | - | - | >240 | 42 | CI | -/- | | -/- | |
| 31 | 12 | - | - | 180 | 47 | CI | -/- | | -/- | |
| 32 | 14 | - | - | 220 | 51 | CI | -/- | | -/- | |
| 33 | 14 | - | + | >240 | 68 | CI | -/- | | -/- | |
| 34 | 16 | + | + | >240 | 20 | AI | +/+ | +/- | +/+ | +/+ |
| 35 | 13 | - | - | >240 | 43 | CI | -/- | | -/- | |
| 36 | 15 | - | + | >240 | 44 | CI | -/- | -/- | -/- | -/- |
| 37 | 11 | - | - | 220 | 71 | CI | -/- | | -/- | |
| 38 | 13 | - | - | 240 | 65 | CI | -/- | | -/- | |
| 39 | 18 | - | - | >240 | 49 | CI | -/- | | -/- | |
| 40 | 12 | - | - | 118 | 46 | CI | -/- | | -/- | |
| 41 | 16 | - | - | 200 | 29 | IA | -/- | -/- | -/- | -/- |
| 42 | 12 | - | + | 180 | 39 | CI | -/- | | -/- | |
| 43 | 15 | - | + | >240 | 19 | AI | +/+ | -/- | +/+ | -/- |
| 44 | 10 | - | - | >240 | 61 | CI | -/- | | -/- | |
| 45 | 14 | - | - | >240 | 42 | CI | -/- | | -/- | |
| 46 | 11 | - | - | 140 | 43 | CI | -/- | | -/- | |
| 47 | 8 | - | - | 220 | 52 | CI | -/- | | -/- | |
| 48 | 10 | - | + | 240 | 41 | CI | -/- | | -/- | |
| 49 | 9 | - | - | >240 | 42 | CI | -/- | | -/- | |
| 50 | 11 | - | - | >240 | 52 | CI | -/- | | -/- | |
| 51 | 12 | - | + | 220 | 46 | CI | -/- | | -/- | |
| 52 | 12 | - | - | >240 | 44 | CI | -/- | | -/- | |
| 53 | 15 | - | - | 240 | 46 | CI | -/- | | -/- | |
| 54 | 16 | + | + | 114 | 20 | AI | +/+ | +/+ | +/+ | +/+ |
| 55 | 17 | - | - | >240 | 55 | CI | -/- | | -/- | |
| 56 | 10 | - | + | 240 | 51 | CI | -/- | | -/- | |
| 57 | 9 | - | - | >240 | 50 | CI | -/- | | -/- | |

AI: Acute Infection, CI: Chronic Infection, IA: Intermediate Avidity, AF: Amniotic Fluid, IU: International Unit
Duplicate assays results are given for DNA amplification.

The IgG ELISA antibodies were evaluated with the following IU: between 80 and 220 in 20 women (35%) and 240 in 37 women (64.9%). For IgM antibodies, 27 (47.3%) of 57 cases tested positive with high titers. The IgA antibodies were found in 7 out of 57 (12.2%) samples (Tab. 3).

Table 3: Rates of *Toxoplasma* acute infection among the study pregnant women. Diagnosis was performed on blood and amniotic fluid samples.

| Trimester | Serological Results | | | | | | PCR Results | | | | Diagnosis (AI) Nbr (%) | | | | | |
|-----------|---------------------|---------|-------|---------|-------------|--------|-------------|---------|----------|---------|---------------------------|---------|------|---------|------|---------|
| | IgA | | IgM | | Low Avidity | | B1 gene | | P30 gene | | | | | | | |
| | Nbr | (%) | Nbr | (%) | Nbr | (%) | Blood | AF | Blood | AF | | | | | | |
| | Nbr | (%) | Nbr | (%) | Nbr | (%) | Nbr | (%) | Nbr | (%) | Nbr | (%) | | | | |
| First | 1/57 | (1.75) | 12/57 | (21.05) | 4/57 | (7.01) | 1/57 | (1.75) | 0/14 | (0.00) | 1/57 | (1.75) | 0/14 | (0.00) | 1/57 | (1.75) |
| Second | 7/57 | (12.28) | 15/57 | (26.31) | 5/57 | (8.77) | 8/57 | (14.03) | 4/14 | (28.57) | 8/57 | (14.03) | 4/14 | (28.57) | 8/57 | (14.03) |

AF : Amniotic Fluid
AI : Acute Infection

Among the 57 women, a total of 30 (52,6%) sera were IgG+/IgM-, while 27 (47.3%) sera were IgG+/IgM+. No sera sample was IgG-/IgM+.

A possible acute infection was suspected for 14 women on the basis of a combination of positive specific IgG/IgM and/or IgA, using two blood samples from each patient, with respectively an interval of 21 days.

IgG Avidity

Toxoplasma IgG Avidity assay has been performed on 57 sera with IgG positive results. High avidity antibodies (indicative of chronic toxoplasmosis) were present in 45 (78.9%) women ; intermediate avidity was determined for 3 (5.2%) women and low IgG avidity antibodies (indicative of acute toxoplasmosis) were found in 9 (15.7%) women, without evidence of *Toxoplasma* infection (Tab. 2). Therefore, 9 out 14 suspected infected women showed low IgG avidity which confirmed an acute infection.

Women, with positive IgM and IgA, were shown to be recently infected indicating an active toxoplasmosis infection (Tab. 2). All subjects presenting an acute toxoplasmosis were at least in the first (1 women out 9) or second (8 women out 9) trimesters of their pregnancies. Therefore, toxoplasmosis infection occurred most likely before or just after conception with a substantial risk for the fetus.

Polymerase chain reaction assay

The PCR results are summarized in Table 2. *T.gondii* DNA was detected by PCR targeting of the B1 and P30 genes in 9 of 57 (15.7%) blood samples and 4 of 14 (28.5%) AF samples obtained from pregnant women. PCR positive

results with the AF samples demonstrated a congenital toxoplasmosis. A total of 8 women out 9 were in the second trimester of their pregnancies (Tab. 3).

All the PCR positive cases were seropositive ; these included 7 samples (12.2%) that were positive for IgG, IgM and IgA antibodies and 2 (3.5%) samples that were positive for both IgM and IgG antibodies. A high IgG avidity and a negative PCR results excluded recent *Toxoplasma* infection in the other women. With regard to positive PCR and low IgG avidity results, 7/9 patients have an IgG-ELISA value \geq 240 IU and a positive IgA antibodies. Viewed separately, IgG avidity alone didn't demonstrate the acute or chronic infectious status in 3 women who showed an intermediate IgG avidity, whereas PCR gave negative signals with both gene targets and demonstrate a chronic infectious status for these women.

The PCR-ELISA targeting the P30 gene had a lowest sensitivity compared to the nested PCR targeting the B1 gene. In fact, when PBL and AF samples were used, only one assay out of two duplicate tests returned positive (patients 1 for PBL samples and patients 15 and 34 for AF). No PCR product was obtained with the negative controls in any experiment.

Discussion:

When a *T. gondii* primary infection is acquired during pregnancy, the parasite may be transmitted to the fetus. The parasite reaches the fetus transplacentally, causing various degrees of damages, depending on: the virulence of the parasite, the immune response of the mother and at what trimester the infection was acquired, resulting in fetal death or in severe clinical symptoms⁶. Pregnant

women are frequently asymptomatic, making a diagnosis difficult. Determination of recently acquired *T. gondii* infection in pregnant women must be made as early as possible to begin an adequate anti-parasitary treatment which can improve the prognosis¹⁹.

Currently, the diagnosis of toxoplasmosis is based on immunological testing that give the titer of circulating antibodies. The presence of specific, IgM²⁰ or IgA,^{21,22} may help to identify recent infection. However, increased levels of IgG and IgM antibodies do not distinguish a recent infection from one acquired a long time before. Therefore, a rapid and effective diagnosis is crucial to initiate an adequate treatment.

In the present study, the tests we used for clarifying the serological status of pregnant women showed IgG and/or IgM anti-*Toxoplasma* antibodies for 57 (39.8%) out of 143 women, which represent the global prevalence of anti-*T. gondii* IgG antibodies in this population. *Toxoplasma* infection during pregnancy was suspected among 14 women according to respective level of anti-*Toxoplasma* IgG and IgM in the first and second samples. On the other hand, results revealed higher IgA antibody titers from acutely infected pregnant women which indicates that in the presence of *Toxoplasma* specific IgG and IgM antibodies, the additional presence of IgA was sufficient to identify the acquisition of infection within the previous 8 to 16 weeks. There is an association between the high level of IgA and IgM which may indicate acute phase of toxoplasmosis. It has faster kinetics, suggesting that the infection occurred less than eight months previously^{23,24}. IgA antibody determination seems to be important for screening of pregnant women and for prenatal diagnosis.

When using the presence of specific IgM as criteria for identifying *T. gondii* infection in early pregnancy, many women will be falsely identified as possibly infected and unnecessarily undergo diagnostic amniocentesis and anti-parasitic treatment. In fact, true positive results must be carefully interpreted²⁵ as IgM antibodies might persist for years after primary infection (residual IgM)^{11,26}. This fact has limited the use of these methods, because it is not possible to determine if the patient has an acute infection or if the infection had occurred months before²⁷. Serological testing may fail during the active phase of *T. gondii* infection because the antibodies titres are low; therefore, the high risk of congenital toxoplasmosis of a fetus may be undetected because the pregnant mother might test

negative during the active phase of *T. gondii* infection. The ideal situation for the diagnosis of *Toxoplasma* infection in pregnancy would be to have an antibody-negative sera sample collected before conception or at the beginning of pregnancy. However, this was not possible in this study.

In combination with the serological conventional tests, IgG avidity is an auxiliary test which permits to differentiate past and present *Toxoplasma* infection when the IgM serological reaction is positive in an asymptomatic patient^{28,29,30}. In 1989, Hedman et al.²⁸ introduced the IgG avidity method for detecting recently acquired *Toxoplasma* infection, based on the strength of the binding of specific IgG to multivalent *Toxoplasma* antigen³¹ and then on the elution of low avidity antibodies by a protein-denaturing agent, mostly urea^{32,33}. During the course of the immune response, there is maturation of antibody affinity that increases progressively over weeks or months. Increase in IgG affinity result from an antigen-driven B-cell selection process, resulting in an increase in complementarity of the antigen-antibody-binding site³⁴. This binding strength was found to be low in acute phase and high in chronic phase of toxoplasmosis^{35,36}; therefore, detection of a low IgG avidity is a reliable indicator for recent toxoplasmosis, whereas a high avidity shows that the infection occurred in the previous 4-5 months^{37,38}. This is most useful in pregnant women in their first months of gestation who have a positive test for both IgG and IgM *Toxoplasma* antibodies³⁴. In this study, recent infection in 9 pregnant women was confirmed by the low avidity index found by IgG avidity ELISA. In fact, we showed that a low avidity index associated with IgG, IgM and/or IgA seroreactivity, is a good indicator that an acute *T. gondii* infection within the last 4 months has been occurred. Among 57 seropositive women, the measure of avidity on the first sera sample have allowed us to take accurate conclusions in 94.7% of cases. The antibody assay combinations and comparison between conventional ELISA and IgG avidity have proven to be very useful. Lecolier and Pucheu,³⁹ concluded that the *Toxoplasma*-specific IgG avidity test should be performed with the first blood sample collected in early pregnancy to exclude acute infection during gestation.

For three patients the avidity index showed a borderline result. When avidity is low or borderline it may be misleading and a more careful interpretation is critical.

Low-avidity results may persist for as long as 1 year and should not be considered as a sufficient argument to confirm a recent seroconversion and even less to prescribe invasive procedures like amniocentesis³⁴. In these cases direct detection of the parasite is necessary for a definitive diagnosis.

The use of the PCR test enable the rapid detection of specific *Toxoplasma* genes and its combination with serological tests carried out on PBL and AF, facilitate earlier diagnosis of congenital toxoplasmosis. Among the many factors influencing the PCR outcome, the choice of the DNA target and primers is generally considered as essential. Few DNA target loci have been described for *Toxoplasma* PCR, but different primer pairs have been used in different assays. The principal gene target remains the 35-fold repetitive and conserved B1 gene. The detection level of PCR is 1 to 10 parasites in the presence of 10⁵ human leucocytes¹⁷. In our study, *T. gondii* DNA could be detected in 9 women who showed positive IgG and IgM antibodies as well as low IgG avidity suggesting that these women may have acquired infection during pregnancy. With regards to the PCR assay by the use of PBL and AF, both B1 and P30 primer sets performed quite equally well and therefore appear adequate for *Toxoplasma* identification; but, with primer set P30, an additional step (achieved through an ELISA–PCR assay) for confirming the identity of the PCR product is of utter importance. However, B1 gene proved valuable PCR for *T. gondii* detection better than P30 gene. Our results showing 3 false negative PCR (Tab. 2), are in agreement with those of Bastien⁴⁰ who validate the current choice targeting B1 gene, which appear clearly more sensitive than assays targeting the single copy P30 gene.

The PCR results were in concordance with those of IgG avidity test. Moreover, PCR was very helpful in cases of intermediat avidity. 3 cases were IgG avidity borderline but PCR negative.

Based on the results of this study, the IgG avidity and the PCR tests performed better than the conventional ELISA for the diagnosis of *Toxoplasma* infection in pregnant women.

When only conventional ELISA was used, 24.5% (14 of 57) acute infections were suspected. When ELISA and IgG avidity were combined, 3 suspected infections out of 14 (05.2%) yielded an intermediat avidity. When ELISA,

IgG avidity, and PCR findings were combined, the acute toxoplasmosis of pregnant women could be demonstrated in 15.7% of cases (9 of 57). This study confirms the complementary need of the techniques used for the screening of pregnant women, but some authors recommend PCR than most serologic techniques¹³

Conclusion:

In this study, the conventional serodiagnosis of toxoplasmosis, on the basis of the first and the second sera sample, was sufficient to determine the serological status of most women and the demonstration of IgA antibody appears useful for diagnosis of *Toxoplasma* infection. However, this is was not possible for some women. The IgG avidity assay has been demonstrated to have the utility to exclude recent infection in early pregnancy for women who otherwise, on the basis of a positive specific IgM result, would have been identified as having a recent infection. From these results it can be concluded that IgG avidity, performed in single samples from positive anti-*Toxoplasma* IgM pregnant women, is a valuable diagnostic tool. Overmore, single PCR-negative samples in conjunction with an IgG/IgM positive test result could confirm a past infection in the presence of serologic results that are difficult to interpret, especially for intermediate avidity.

The main finding of our study was the significant association between high IgG anti-*T. gondii* titers, low index avidity and PCR detection of *T. gondii* DNA and the diagnosis of acute toxoplasmosis. Moreover, the molecular biology technique was useful in pregnant women with seroconversion, to exclude the presence of *T. gondii* DNA in AF. These women will be saved from unnecessary anxiety, additional examinations and treatment. However, to the best of our knowledge, no studies have been published using both IgG avidity and PCR for the diagnosis of toxoplasmosis on pregnant women in Algeria. We hope that our study will open new perspectives for the systematic introduction of these techniques in the diagnosis of toxoplasmosis.

Conflict of interest:

The authors declare that they have no conflicts of interest.

References:

1. Petersen E, Dubey JP. Biology of *Toxoplasma gondii*. In: Joynson DH, Wreghitt T, editors. *Toxoplasmosis:*

- a Comprehensive Clinical Guide. Cambridge University Press; 2001 pp 1-49.
2. Remington JS, McLeod R, Wilson CB, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 7th ed. *Pennsylvania Elsevier*; 2011 pp 918-1041.
 3. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. *Clinical Infectious Diseases* 1992;15(2):211-222. <http://www.ncbi.nlm.nih.gov/pubmed/1520757>
 4. Edward CG. Toxoplasmosis. *Medicine*. 2014;42(1):31-33. http://ac.els-cdn.com/S1357303913002922/1-s2.0-S1357303913002922-main.pdf?_tid=a59e5c7a-032d-11e5-adea-00000aab0f27&acd-nat=1432593209_8219c53ac4c7ca89266f6a9a66c458e2
 5. Wrong S, Remington JS. Toxoplasmosis in pregnancy. *Clinical Infectious Diseases* 1994;18(6):853-861. <http://www.ncbi.nlm.nih.gov/pubmed/8086543>
 6. Dunn, D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. *Lancet*. 1999;353:1829-1833. <http://www.ncbi.nlm.nih.gov/pubmed/10359407>
 7. Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. *Expert Review of Anti-Infective Therapy* 2012;10:815-828. <http://informahealthcare.com/doi/abs/10.1586/eri.12.58>
 8. Stray-Pedersen B. Treatment of toxoplasmosis in the pregnant mother and newborn child. *Scandinavian Journal of Infectious Disease Supplement* 1992;84:23-31. <http://www.ncbi.nlm.nih.gov/pubmed/1290070>
 9. James GS, Sintchenko VG, Dickeson DJ, Gilbert GL. Comparison of cell culture, mouse inoculation, and PCR for detection of *Toxoplasma gondii*: effects of storage conditions on sensitivity. *Journal of Clinical Microbiology* 1996;34(6):1572-1575. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC229067/>
 10. Liesenfeld O, Montoya JG, Kinney S, Press C, Remington JS. Effect of testing for IgG Avidity in the diagnosis of *Toxoplasma gondii* infection in pregnant women: Experience in a US Reference Laboratory. *Journal of Infectious Diseases* 2001;183(8):1248-1253. <http://jid.oxfordjournals.org/content/183/8/1248.full.pdf>
 11. Lappalainen M, Koskela P, Koskiniemi M, et al. Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. *Journal of Infectious Diseases* 1993;167(3):691-697. <http://www.ncbi.nlm.nih.gov/pubmed/8440939>
 12. Delhaes L, Yera H, Ache S, Tsatsaris V, Houfflin-Debarge V. Contribution of molecular diagnosis to congenital toxoplasmosis. *Diagnostic Microbiology and Infectious Disease* 2013;76:244-247. <http://www.ncbi.nlm.nih.gov/pubmed/23518182?dopt=Abstract>
 13. Kaiser K, Van Loon AM, Pelloux H, Ferrandiz J, Picot S, Wallace P, Peyron F. Multicenter proficiency study for detection of *Toxoplasma gondii* in amniotic fluid by nucleic acid amplification methods. *Clin Chim Acta* 2007;375(1-2):99-103. <http://www.ncbi.nlm.nih.gov/pubmed/16860303?dopt=Abstract>
 14. Jenum P, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary *Toxoplasma gondii* infection in early pregnancy by determination of antitoxoplasma immunoglobulin G Avidity. *Journal of Clinical Microbiology* 1997;35(8):1972-1977. <http://www.ncbi.nlm.nih.gov/pubmed/9230365>
 15. Villard O, Breit L, Cimon B, et al. The French National Reference Center for Toxoplasmosis Network. Comparison of four commercially available avidity tests for *Toxoplasma gondii*-specific IgG antibodies. *Clinical Vaccine immunology* 2013;20(2):197-204. <http://www.ncbi.nlm.nih.gov/pubmed/23239801>
 16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extraction DNA from human nucleated cells. *Nucleic Acide Research* 1988;16(3):1215-1217. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC334765/>
 17. Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, *Toxoplasma gondii* by polymerase chain reaction. *Journal of Clinical Microbiology* 1989;27(8):1787-1792. <http://www.ncbi.nlm.nih.gov/pubmed/2768467>
 18. Moleon I, Beuchamp P, Cesbron MF, Tourvieille B. Cloning of the gene encoding the p30 antigen of *Toxoplasma gondii* by PCR to insert it in transgenic mice. *Archive of Medical Research* 1994;25(4):463-466. <http://www.ncbi.nlm.nih.gov/pubmed/7858408>
 19. Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplas-

- mosis: outcome of pregnancy and infant follow-up after in utero treatment. *Journal of Pediatrics* 1989;115(5):765-769. <http://www.ncbi.nlm.nih.gov/pubmed/2681638>
20. Desmonts G, Naot Y, Remington JS. Immunoglobulin M immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired *Toxoplasma* infections. *Journal of Clinical Microbiology* 1981;14(5):486-491. <http://www.ncbi.nlm.nih.gov/pubmed/7031082>
21. Pinon JM, Thoannes H, Pouletty PH, Poirriez J, Damiens J, Pelletier P. Detection of IgA specific for toxoplasmosis in serum and cerebrospinal fluid using a non-enzymatic IgA-capture assay. *Diagnostic Immunology* 1986 (5);4:223-227. <http://www.ncbi.nlm.nih.gov/pubmed/3791840>
22. Decoster A, Darcy F, Caron A, Capron A. IgA antibodies against P30 as markers of congenital and acute toxoplasmosis. *Lancet* 1988;ii:1104-1107. <http://www.ncbi.nlm.nih.gov/pubmed/2903324>
23. Rodrigues IM, Castro AM, Gomes MB, Amaral WN, Avelino MM. Congenital toxoplasmosis: evaluation of serological methods for the detection of anti-*Toxoplasma gondii* IgM and IgA antibodies. *Memorias do Instituto Oswaldo Cruz* 2009;104:434-440 http://www.scielo.br/scielo.php?pid=S0074-0276200900300006&script=sci_arttext&tlng=pt
24. Francis JM, Joynson DH. Duration of specific immunoglobulin A antibody following acute toxoplasmosis as determined by enzyme immunoassay and immunosorbent agglutination assay. *European Journal of Clinical and Microbiological Infectious Diseases* 1993;12(7):556-559. <http://www.ncbi.nlm.nih.gov/pubmed/8404920?dopt=Citation>
25. Liesenfeld O, Press C, Montoya J, et al. False-positive results in immunoglobulin (IgM) *Toxoplasma* antibody tests and importance of confirmatory testing: Platelia Toxo- IgM test. *Journal of Clinical Microbiology* 1997;35(1):174-178. <http://www.ncbi.nlm.nih.gov/pubmed/8968902?dopt=Citation>
26. Wong SY, Hadju MP, Ramirez R, Thulliez P, McLeod R, Remington JS. Role of specific immunoglobulin E in diagnosis of acute *Toxoplasma* infection and toxoplasmosis. *Journal of Clinical Microbiology* 1993;31(11):2952-2959. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC266169/>
27. Wilson M, Remington JS, Clavet C, Varney G, Press C. Evaluation of six commercial kits for the detection of immunoglobulin M antibodies to *Toxoplasma gondii*, the FDA toxoplasmosis Ad Hoc Working Group. *Journal of Clinical Microbiology* 1997;35(12):3112-3115. <http://www.ncbi.nlm.nih.gov/pubmed/9399504>
28. Fricker-Hidalgo H, Saddoux C, Suchel-Jambon AS, Romand S, Foussadier A, Pelloux H, Thulliez P. New Vidas assay for *Toxoplasma*-specific IgG avidity: evaluation on 603 sera. *Diagnostic Microbiology and Infectious Disease* 2006;56:167-172. <http://www.ncbi.nlm.nih.gov/pubmed/16725296>
29. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. *Annals Ist Super Sanita* 2004;40(1):81-88. <http://www.ncbi.nlm.nih.gov/pubmed/15269456>
30. Pelloux H, Brun E, Vernet G, et al. Determination of anti-*Toxoplasma gondii* immunoglobulin G avidity: Adaptation to the Vidas system (BioMerieux). *Diagnosis of Microbiological Infectious Diseases* 1998;32(2):69-73. <http://www.ncbi.nlm.nih.gov/pubmed/9823527>
31. Roitt IM. Essential immunology. Blackwell Scientific Publications: Oxford 1988 pp 60-63.
32. Candolfi E, Pastor R, Huber R, Filisetti D, Villard O. IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. *Diagnostic and Microbiological Infectious Diseases* 2007;58(1):83-88. <http://www.ncbi.nlm.nih.gov/pubmed/17368807>
33. Petersen E, Borobio MV, Guy E, et al. European multicenter study of the LIAISON automated diagnostic system for determination of *Toxoplasma gondii*-specific immunoglobulin G (IgG) and IgM and the IgG avidity index. *Journal of Clinical Microbiology* 2005;43(4):1570-1574. <http://www.ncbi.nlm.nih.gov/pubmed/15814967>
34. Remington JS, Thulliez F, Montoya JG. Recent developments for diagnosis of Toxoplasmosis. *Journal of Clinical Microbiology* 2004;42(3):941-945. <http://www.ncbi.nlm.nih.gov/pubmed/15004036>
35. Iqbal J, Khalid N. Detection of acute *Toxoplasma gondii* infection in early pregnancy by IgG avidity and PCR analysis. *Journal of Medical Microbiology* 2007;56(11):1495-1499. <http://www.ncbi.nlm.nih.gov/pubmed/17965351>
36. Hedman K, Lappalainen M, Sönderlund M, Hedman L. Avidity of IgG in serodiagnosis of infectious diseases. *Revue of Medicinal Microbiology* 1993;4:123-29.
37. Flori P, Belleste B, Crampe C, et al. A technique for

- dating toxoplasmosis in pregnancy and comparison with the Vidas anti-Toxoplasma IgG avidity test. *Clinical Microbiological Infection* 2008;14(3):242-249. <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2007.01905.x/full>
38. Paul M. Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis. *Clinical Diagnosis of Laboratory Immunology* 1999;6(4):514-518. <http://www.ncbi.nlm.nih.gov/pubmed/10391853>
39. Candolfi E, Pastor R, Huber R, Filisetti D, Villard O. IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. *Diagn Microbiol Infect Dis* 2007;58:83-88. <http://www.ncbi.nlm.nih.gov/pubmed/17368807>
40. Bastien P. Molecular diagnosis of toxoplasmosis. *Trans Royal Society of Tropical Medical Hygiene* 2002;96(1):205-215. <http://www.ncbi.nlm.nih.gov/pubmed/12055840>